Physician profile
Youssef Assioun
NPI 1639370919
$5,246.98
in general payments reported to CMS, 2019-2025
33 companies · $739 in 2025
The $739 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $551 · 2020: $156 · 2021: $155 · 2022: $958 · 2023: $911 · 2024: $1,776 · 2025: $739.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,426.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,426.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,169.35 | 2019-2025 | Mavyret, Rinvoq, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $486.07 | 2019-2024 | Xifaxan, Trulance |
| Pfizer INC. | $411.14 | 2019-2025 | |
| Genzyme Corporation | $406.64 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $394.10 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Gilead Sciences, INC. | $229.38 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $226.09 | 2021-2024 | |
| Celgene Corporation | $150.41 | 2022-2024 | Zeposia |
| Qol Medical, LLC | $145.73 | 2019-2025 | Sucraid, Sucraid |
| Novo Nordisk INC | $144.33 | 2024-2025 | Wegovy |
| Ardelyx, INC. | $136.52 | 2022-2025 | Ibsrela |
| Medtronic, INC. | $135.28 | 2022 | |
| Janssen Biotech, INC. | $134.95 | 2022-2025 | Tremfya, Stelara |
| Regeneron Healthcare Solutions, INC. | $134.40 | 2022-2024 | Dupixent |
| Nevro Corp. | $123.07 | 2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $116.72 | 2024 | Voquezna |
| Erbe USA INC | $113.36 | 2025 | Vio3 |
| Aimmune Therapeutics, INC. | $76.64 | 2024-2025 | Zenpep, Vowst |
| Ipsen Biopharmaceuticals, INC | $69.27 | 2024 | Iqirvo |
| Kci USA, INC. | $66.08 | 2019 | |
| Merck Sharp & Dohme LLC | $49.12 | 2019-2023 | Dificid |
| Madrigal Pharmaceuticals | $40.45 | 2025 | Rezdiffra |
| Capsovision, INC. | $39.02 | 2024-2025 | Capsocam Plus |
| Amgen INC. | $36.88 | 2023 | Avsola, Amjevita |
| Intercept Pharmaceuticals, INC. | $33.16 | 2022-2024 | |
| Nestle Healthcare Nutrition INC. | $32.06 | 2023 | |
| Lilly USA, LLC | $26.92 | 2024 | Omvoh |
| Daiichi Sankyo INC. | $24.68 | 2022 | |
| Dova Pharmaceuticals | $24.15 | 2019 | |
| Redhill Biopharma INC. | $20.24 | 2023 | |
| Braintree Laboratories, INC. | $19.66 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.82 | 2024 | Cyltezo |
| Ironwood Pharmaceuticals, INC | $15.29 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Youssef Assioun listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.